Cargando…
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
Purpose: This study aimed to elucidate the optimal cumulative cisplatin dose (CCD) for concurrent chemoradiotherapy (CCRT) according to the post-induction chemotherapy (IC) plasma Epstein–Barr virus (EBV) DNA level. Results: EBV DNA was detected and undetected in 179 and 370 patients, respectively....
Autores principales: | Liu, Sai-Lan, Sun, Xue-Song, Liu, Li-Ting, Sun, Rui, Luo, Dong-Hua, Chen, Qiu-Yan, Lin, Huan-Xin, Yuan, Li, Tang, Lin-Quan, Guo, Ling, Mai, Hai-Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138583/ https://www.ncbi.nlm.nih.gov/pubmed/32221045 http://dx.doi.org/10.18632/aging.102920 |
Ejemplares similares
-
Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level
por: Liu, Sai-Lan, et al.
Publicado: (2020) -
Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma
por: Zhang, Jian, et al.
Publicado: (2018) -
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
por: Lv, Jia‐Wei, et al.
Publicado: (2018) -
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2018) -
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)